Advanced

Amount of DNA in plasma and cancer risk: A prospective study

Gormally, E; Hainaut, P; Caboux, E; Airoldi, L; Autrup, H; Malaveille, C; Dunning, A; Garte, S; Matullo, G and Overvad, K, et al. (2004) In International Journal of Cancer 111(5). p.746-749
Abstract
Levels of plasma DNA concentrations in cancer patients have been shown to be higher than the plasma DNA concentrations found in healthy subjects. The value of plasma DNA levels for development of neoplastic or pulmonary disease was evaluated in a large prospective study. Plasma samples (n = 1, 184) were analyzed from 776 controls, 359 cases of cancer (lung, bladder, oral cavity, pharynx, larynx, leukemia) and 49 deaths from chronic obstructive pulmonary disease (COPD), including never smokers and ex-smokers, from 9 countries across Europe. The amount of plasma DNA was variable across the European Prospective Investigation into Cancer and Nutrition (EPIC) centers. High DNA concentrations in some centers might be due to the type of... (More)
Levels of plasma DNA concentrations in cancer patients have been shown to be higher than the plasma DNA concentrations found in healthy subjects. The value of plasma DNA levels for development of neoplastic or pulmonary disease was evaluated in a large prospective study. Plasma samples (n = 1, 184) were analyzed from 776 controls, 359 cases of cancer (lung, bladder, oral cavity, pharynx, larynx, leukemia) and 49 deaths from chronic obstructive pulmonary disease (COPD), including never smokers and ex-smokers, from 9 countries across Europe. The amount of plasma DNA was variable across the European Prospective Investigation into Cancer and Nutrition (EPIC) centers. High DNA concentrations in some centers might be due to the type of population recruited and/or the treatment of the samples. An elevated and statistically significant odds ratio (OR) was found for COPID deaths (OR = 2.53; 95% CI = 1.06-6.02), while nonsignificant increased ORs were present for oral cancers, cancers of the pharynx and larynx and leukemia. When the analyses were stratified by time since recruitment (below or above 36 months), the increased ORs were limited to the more recent period of recruitment, i.e., a time elapsed between blood drawing and disease onset lower than 36 months. This was particularly true for COPID deaths (OR = 12.7; 95% CI = 1.57-103) and leukemia (OR = 2.37; 95% Cl = 1.20-4.67). (C) 2004 Wiley-Liss, Inc. (Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
prospective studies, plasmatic DNA, cancer, molecular repidemiology
in
International Journal of Cancer
volume
111
issue
5
pages
746 - 749
publisher
John Wiley & Sons
external identifiers
  • wos:000223263700014
  • pmid:15252845
  • scopus:4043074258
ISSN
0020-7136
DOI
10.1002/ijc.20327
language
English
LU publication?
yes
id
f34b42bf-cd69-4658-82ab-021287f340c8 (old id 270806)
alternative location
http://www.ncbi.nlm.nih.gov/sites/entrez?cmd=Retrieve&db=PubMed&list_uids=15252845&dopt=Citation
date added to LUP
2007-08-02 13:45:25
date last changed
2017-10-22 03:50:42
@article{f34b42bf-cd69-4658-82ab-021287f340c8,
  abstract     = {Levels of plasma DNA concentrations in cancer patients have been shown to be higher than the plasma DNA concentrations found in healthy subjects. The value of plasma DNA levels for development of neoplastic or pulmonary disease was evaluated in a large prospective study. Plasma samples (n = 1, 184) were analyzed from 776 controls, 359 cases of cancer (lung, bladder, oral cavity, pharynx, larynx, leukemia) and 49 deaths from chronic obstructive pulmonary disease (COPD), including never smokers and ex-smokers, from 9 countries across Europe. The amount of plasma DNA was variable across the European Prospective Investigation into Cancer and Nutrition (EPIC) centers. High DNA concentrations in some centers might be due to the type of population recruited and/or the treatment of the samples. An elevated and statistically significant odds ratio (OR) was found for COPID deaths (OR = 2.53; 95% CI = 1.06-6.02), while nonsignificant increased ORs were present for oral cancers, cancers of the pharynx and larynx and leukemia. When the analyses were stratified by time since recruitment (below or above 36 months), the increased ORs were limited to the more recent period of recruitment, i.e., a time elapsed between blood drawing and disease onset lower than 36 months. This was particularly true for COPID deaths (OR = 12.7; 95% CI = 1.57-103) and leukemia (OR = 2.37; 95% Cl = 1.20-4.67). (C) 2004 Wiley-Liss, Inc.},
  author       = {Gormally, E and Hainaut, P and Caboux, E and Airoldi, L and Autrup, H and Malaveille, C and Dunning, A and Garte, S and Matullo, G and Overvad, K and Tjonneland, A and Clavel-Chapelon, F and Boffetta, P and Boeing, H and Trichopoulou, A and Palli, D and Krogh, V and Tumino, R and Panico, S and Bueno-De-Mesquita, HB and Peeters, PH and Lund, E and Gonzalez, CA and Martinez, C and Dorronsoro, M and Barricarte, A and Tormo, MJ and Quiros, JR and Berglund, Göran and Hallmans, G and Day, NE and Key, TJ and Veglia, F and Peluso, M and Norat, T and Saracci, R and Kaaks, R and Riboli, E and Vineis, P},
  issn         = {0020-7136},
  keyword      = {prospective studies,plasmatic DNA,cancer,molecular repidemiology},
  language     = {eng},
  number       = {5},
  pages        = {746--749},
  publisher    = {John Wiley & Sons},
  series       = {International Journal of Cancer},
  title        = {Amount of DNA in plasma and cancer risk: A prospective study},
  url          = {http://dx.doi.org/10.1002/ijc.20327},
  volume       = {111},
  year         = {2004},
}